Novostia Secures $6.5 Million in Seed Funding to Advance Development of Novel Heart Valve Implant

VCBeat (WeChat Official Account: vcbeat) has learned that Novostia, a Swiss developer of cardiovascular devices, recently announced the completion of a $6.5 million seed funding round. The proceeds from this round will be used to further develop its novel heart valve device.

Novostia is a privately held medical device company founded in Switzerland in 2017. The company is dedicated to improving the quality of life for millions of patients worldwide suffering from aortic and mitral valve diseases, while simultaneously reducing overall healthcare costs. Novostia holds multiple technology patents and is a global leader in fluid dynamics, advanced biomaterials, high-precision manufacturing, and medical laboratory research.

In terms of talent development, Novostia has been committed to recruiting renowned figures in the medical industry from around the world. It is reported that the company has developed a new type of artificial heart valve suitable for patients of all age groups. This artificial heart valve was jointly designed by Dr. Didier Lapeyre, a French cardiovascular surgeon, and Philippe Perrier, a medical device designer. According to Novostia’s official website, thanks to its unique anatomical trileaflet design and novel high-performance biocompatible materials, this new artificial heart valve features being free of anticoagulants, lifelong durability, and silent operation.

According to foreign media reports, cardiovascular disease is a leading cause of death, with the global number of deaths from cardiovascular disease rising year by year. However, due to changes in lifestyle and the difficulties associated with long-term prevention and control, the incidence of acute coronary syndrome is currently on the rise. For some critically ill patients, surgery and medical devices remain the only options.

Significant demand has also translated into a substantial market share. Data provided by Novostia shows that the global market size for interventional cardiovascular disease treatment has increased year by year, surpassing the $20 billion mark in 2014. In 2016, the global market size for interventional cardiovascular disease treatment reached $29.8 billion. By 2018, the global cardiac medical device market had grown to $48 billion, with high-end interventional consumables—holding the largest share of the total market—characterized by extremely high technical barriers. This is precisely the domain that Novostia focuses on and delves into deeply.

“I am impressed by the novel heart valve device developed by Novostia and look forward to its early market availability. I believe this device will benefit tens of thousands of patients, particularly young people,” said Professor Thierry Carrel of Bern University Hospital in Switzerland.

“Our product can improve the quality of life for individuals with prosthetic heart valves, particularly children and young patients, while reducing overall healthcare costs. We appreciate the trust and support of our investors and look forward to delivering this long-awaited innovative product to patients and physicians,” said Geoffroy Lapeyre, CEO of Novostia, in an interview with the media.

(Compiled by Hu Xuan)